ValuEngine lowered shares of PTC Therapeutics (NASDAQ:PTCT) from a sell rating to a strong sell rating in a research note released on Friday morning.
Several other equities research analysts have also commented on PTCT. Barclays reduced their price target on shares of PTC Therapeutics from $22.00 to $15.00 and set an equal weight rating for the company in a research report on Friday, September 29th. Royal Bank of Canada reaffirmed a sector perform rating on shares of PTC Therapeutics in a research report on Friday, September 29th. Credit Suisse Group reissued an outperform rating and issued a $25.00 target price on shares of PTC Therapeutics in a report on Tuesday, September 26th. JPMorgan Chase & Co. reissued a neutral rating on shares of PTC Therapeutics in a report on Tuesday, September 26th. Finally, Cowen reissued a hold rating on shares of PTC Therapeutics in a report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of $18.75.
Shares of PTC Therapeutics (NASDAQ PTCT) opened at $16.68 on Friday. PTC Therapeutics has a 52-week low of $8.12 and a 52-week high of $22.00. The company has a market cap of $692.05, a PE ratio of -5.77 and a beta of 1.23. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08.
TRADEMARK VIOLATION WARNING: “PTC Therapeutics (PTCT) Cut to Strong Sell at ValuEngine” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/01/ptc-therapeutics-ptct-cut-to-strong-sell-at-valuengine.html.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.